The effect of paliperidone extended release on subjective well-being and responses in patients with schizophrenia.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  Progress in Neuro-psychopharmacology and Biological Psychiatry

• Publication date

  2012-08-07

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1016/j.pnpbp.2012.04.004PMID 22516251
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Diagnostic and Statistical Manual of Mental Disorders

  2013cited by this paper
• Remission as perceived by people with schizophrenia, family members and psychiatrists

  2012cited by this paper
• A Validation Study of the Korean Version of SPAN

  2011cited by this paper
• Response and remission of subjective well-being in patients suffering from schizophrenia spectrum disorders

  2011cited by this paper
• Social Interaction and Drug Attitude Effectiveness in Patients with Schizophrenia

  2011cited by this paper
• Medication satisfaction in schizophrenia: a blinded-initiation study of paliperidone extended release in patients suboptimally responsive to risperidone

  2010cited by this paper
• Clinician-rated functioning and patient-rated quality of life in schizophrenia: implications of their correspondence for psychopathology and side effects.

  2010cited by this paper
• The pharmacokinetics of paliperidone versus risperidone.

  2010cited by this paper
• Subjective wellbeing under quetiapine treatment: effect of diagnosis, mood state, and anxiety.

  2009cited by this paper
• Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release

  2009cited by this paper
• Effects of switching to long‐acting injectable risperidone from oral atypical antipsychotics on cognitive function in patients with schizophrenia

  2009cited by this paper
• Assessment of clinical and metabolic status, and subjective well-being, in schizophrenic patients switched from typical and atypical antipsychotics to ziprasidone

  2008cited by this paper
• The dilemma of insight into illness in schizophrenia: self- and expert-rated insight and quality of life

  2008cited by this paper
• Rates and predictors of remission and recovery during 3 years in 392 never‐treated patients with schizophrenia

  2008cited by this paper
• Paliperidone extended-release tablets in schizophrenia patients previously treated with risperidone

  2008cited by this paper
• Quality of life and subjective well-being during treatment with antipsychotics in out-patients with schizophrenia.

  2007cited by this paper
• Association of subjective well-being, symptoms, and side effects with compliance after 12 months of treatment in schizophrenia.

  2007cited by this paper
• A Validation Study of the Korean Version of the Subjective Well-being Under Neuroleptic Treatment Scale-Short Form

  2007cited by this paper
• Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride

  2007cited by this paper
• Correlation of physician and patient rated quality of life during antipsychotic treatment in outpatients with schizophrenia.

  2007cited by this paper
• A Validation Study of the Korean-Version of the Personal and Social Performance Scale

  2006cited by this paper
• Randomized controlled trial of the effect on Quality of Life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1).

  2006cited by this paper
• Predictors of antipsychotic medication adherence in patients recovering from a first psychotic episode.

  2006cited by this paper
• Survey of medication adherence in patients with schizophrenia—Korean ADHES data

  2006cited by this paper
• Sequence-based CYP2D6 Genotyping in the Korean Population

  2006cited by this paper
• Clinical spectrum of the osmotic-controlled release oral delivery system (OROS*), an advanced oral delivery form

  2006cited by this paper
• The Effects of Olanzapine in the Maintenance Treatment of Outpatients with Schizophrenia and Other Psychotic Disorders

  2006cited by this paper
• A review of pharmacologic strategies for switching to atypical antipsychotics.

  2005cited by this paper
• Psychometric Properties of Korean Version of Drug Attitude Inventory(KDAI-10)

  2005cited by this paper
• Subjective experiences on antipsychotic medications: synthesis and conclusions

  2005cited by this paper
• An update of fast-off dopamine D2 atypical antipsychotics.

  2005cited by this paper
• Randomized double blind comparison of olanzapine vs. clozapine on subjective well‐being and clinical outcome in patients with schizophrenia

  2005cited by this paper
• PANSS Syndromes and Quality of Life in Schizophrenia

  2005cited by this paper
• Current Issues in Schizophrenia: Overview of Patient Acceptability, Functioning Capacity and Quality of Life

  2004cited by this paper
• Multidimensional Sensory Phenomena in Antipsychotic-Induced Akathisia

  2004cited by this paper
• Increased suicide attempt rate among patients interrupting use of atypical antipsychotics

  2003cited by this paper
• The Clinical Global Impression–Schizophrenia scale: a simple instrument to measure the diversity of symptoms present in schizophrenia

  2003cited by this paper
• Pharmacy Data Identify Poorly Adherent Patients With Schizophrenia at Increased Risk for Admission

  2002cited by this paper
• Indicators of medication compliance in first-episode psychosis.

  2002cited by this paper
• Metric characteristics of the drug‐induced extrapyramidal symptoms scale (DIEPSS): A practical combined rating scale for drug‐induced movement disorders

  2002cited by this paper
• Extrapyramidal symptom profiles in Japanese patients with schizophrenia treated with olanzapine or haloperidol.

  2002cited by this paper
• Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: A new hypothesis.

  2001cited by this paper
• Improvement of schizophrenic patients' subjective well-being under atypical antipsychotic drugs.

  2001cited by this paper
• Good tolerability equals good results: the patient's perspective.

  2001cited by this paper
• Development, reliability and acceptability of a new version of the DSM‐IV Social and Occupational Functioning Assessment Scale (SOFAS) to assess routine social funtioning

  2000cited by this paper
• Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder.

  1999cited by this paper
• Cognitive Dysfunction at Baseline Predicts Symptomatic 1-Year Outcome in First-Episode Schizophrenics

  1999cited by this paper
• Facilitating compliance with antipsychotic medication.

  1998cited by this paper
• Compliance with treatment in schizophrenia: a drug intervention program in a developing country

  1995cited by this paper
• A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables

  1995cited by this paper
• Awareness of illness in schizophrenia and schizoaffective and mood disorders.

  1994cited by this paper
• Subjective response to neuroleptics and outcome in schizophrenia: a re-examination comparing two measures

  1992cited by this paper
• A self-report scale predictive of drug compliance in schizophrenics: reliability and discriminative validity

  1983cited by this paper
• A standardized psychiatric assessment scale for rating chronic psychotic patients

  1977cited by this paper

• Machine learning prediction model of the treatment response in schizophrenia reveals the importance of metabolic and subjective characteristics.

  2024cites this paper
• Modeling the Determinants of Subjective Well-Being in Schizophrenia.

  2024cites this paper
• Effectiveness of Switching to Long-acting Injectable Aripiprazole in Patients with Recent-onset and Chronic Schizophrenia

  2023cites this paper
• Effectiveness of group metacognitive training and cognitive–behavioural therapy in a transdiagnostic manner for young patients with psychotic and non‐psychotic disorders

  2022cites this paper
• The impact of cognitive insight, self-stigma, and medication compliance on the quality of life in patients with schizophrenia

  2018cites this paper
• A systematic review and combined analysis of therapeutic drug monitoring studies for oral paliperidone

  2018cites this paper
• Effects of Group Cognitive-Behavioral Therapy in Young Patients in the Early Stage of Psychosis

  2017cites this paper
• A systematic review and combined analysis of therapeutic drug monitoring studies for long-acting risperidone

  2017cites this paper
• Longitudinal relationship between Personal and Social Performance (PSP) and anxiety symptoms in schizophrenia.

  2016cites this paper
• Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial

  2016cites this paper
• The longitudinal trends in the relationship between drug-induced extrapyramidal symptoms and personal and social performance in a population of the patients with schizophrenia: A latent growth model.

  2016influential citation
• Factors associated with self‐rated sexual function in Korean patients with schizophrenia receiving risperidone monotherapy

  2015cites this paper
• Weight gain and antipsychotics: a drug safety review

  2015cites this paper
• Efficacy and tolerability of paliperidone ER in patients with unsatisfactorily controlled schizophrenia by other antipsychotics: a flexible-dose approach

  2015influential citation
• Refinement of the SWN-20 based on the Rasch rating model.

  2015cites this paper
• Patient-Centered Outcomes with Aripiprazole Once-Monthly for Maintenance Treatment in Patients with Schizophrenia: Results From Two Multicenter, Randomized, Double-Blind Studies.

  2015cites this paper
• Aminotransferase levels as a prospective predictor for the development of metabolic syndrome in patients with schizophrenia

  2014cites this paper
• Lower risk for body weight gain and better control of appetite after switching risperidone to paliperidone in a schizoaffective patient.

  2014cites this paper
• Influencing Factors and Predictors of Early Response in Schizophrenia Patients Receiving the Paliperidone Extended-Release Tablets (Paliperidone ER)

  2013cites this paper
• Efficacy and Safety of Paliperidone Extended Release in Schizophrenia Patients Requiring a Switch in Antipsychotic Medication by Switching Previous Antipsychotics to Paliperidone Extended Release

  2012cites this paper